Abstract 2751
Background
Gastrointestinal stromal tumors (GISTs) are rare mesenchymal tumors of the gastrointestinal (GI) tract. The size, the presence of a c-KIT gene mutation and the mitotic index are used to determine the prognosis and to direct systemic treatment choices. This study evaluated the use of radiomics, a technique which uses algorithms for diagnosing and predicting the c-KIT mutational status and mitotic index of GISTs from medical imaging features.
Methods
A combination of machine learning methods was used to distinguish treatment-naive GISTs from other GI tumors resembling GISTs on imaging, based on clinical and molecular characteristics, as well as imaging features extracted from the contrast-enhanced venous phase computed tomography scans. Evaluation was performed in a 100x random-split cross-validation with 20% of the data for testing.
Results
A total of 242 tumors were used for distinguishing GISTs (n = 123) from non-GISTs (n = 119) including leiomyoma (n = 25), schwannoma (n = 21), gastric carcinoma (n = 25), lymphoma (n = 23) and leiomyosarcoma (n = 25).The non-GISTs were located either gastric (23%) or non-gastric (77%) and the GISTs were located either gastric (63%) or non-gastric (37%). A c-KIT mutation was present in the majority of the GISTs (exon 9 n = 10, exon 11 n = 56, exon 13 n = 2). The dataset originated from 65 different scanners, leading to heterogeneity in the imaging protocols. Imaging feature analyses showed a mean area under the curve (mAUC) of 0.70 (95% confidence interval [CI] 0.63-0.76) for distinguishing GIST from non-GISTs. A mAUC of 0.52 (95% CI 0.32-0.72) was found for predicting all c-KIT mutations, a mAUC of 0.51 (95% CI 0.29-0.72) for predicting a c-KIT exon 9 mutation, and a mAUC of 0.61 (95% CI 0.47-0.74) for predicting a c-KIT exon 11 mutation. The mitotic index was available in 83 patients (≤5/50 high power fields (HPFs) n = 53, 43.1%, >5/50 HPFs n = 33, 26.8%), and showed a mAUC of 0.60 (95% CI 0.47-0.73).
Conclusions
This pilot study showed the potential of radiomics to distinguish GIST from other GI tumors, but no potential in predicting c-KIT mutational status and mitotic index of GISTs. Further optimization and validation of the radiomics model is required to incorporate radiomics in the diagnostic routine of GISTs.
Clinical trial identification
Editorial acknowledgement
M.J. Timbergen and M.P.A. Starmans contributed equally to this study.
Legal entity responsible for the study
The authors.
Funding
The Netherlands Organization for Scientific Research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4242 - HIV, HBV and HCV screening practices in oncology: a cross-sectional interregional survey
Presenter: Isabelle Poizot-Martin
Session: Poster Display session 1
Resources:
Abstract
1267 - Genetic landscape of KEAP1 and NFE2L2 mutated cancers from the AACR GENIE database
Presenter: Mark Zaki
Session: Poster Display session 1
Resources:
Abstract
878 - β-arrestin1 is involved in the Ras-induced malignant transformation
Presenter: Takashi Shibano
Session: Poster Display session 1
Resources:
Abstract
4143 - Incidence of second cancer among PLWHIV: retrospective observational study of a series of 601 patients in the French CANCERVIH network
Presenter: Jean-Philippe Spano
Session: Poster Display session 1
Resources:
Abstract
5145 - A challenging task – Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: the CUPISCO trial experience
Presenter: Chantal Pauli
Session: Poster Display session 1
Resources:
Abstract
1737 - Incidence and Outcome of chronic lymphocytic leukemia with Deletion 17p: An Indian experience; challenges and opportunities
Presenter: Ajay Gogia
Session: Poster Display session 1
Resources:
Abstract
2596 - Driving solo? Investigation into collaborating mutations in SDH-deficient neoplasia
Presenter: Jonathan Killian
Session: Poster Display session 1
Resources:
Abstract
1499 - The potential of a novel antiangiogenic VEGFR1-D2 binding peptide in oncology therapeutics
Presenter: Afsaneh Sadre Momtaz
Session: Poster Display session 1
Resources:
Abstract
1775 - First-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors
Presenter: Mayu Yunokawa
Session: Poster Display session 1
Resources:
Abstract
4584 - First-in-human study of ABBV-621 in patients (pts) with previously treated sold tumors: Dose-optimization cohorts
Presenter: Emiliano Calvo
Session: Poster Display session 1
Resources:
Abstract